Key Stats for REGN Stock
- Past-30-Day Performance: -15%
- 52-Week Range: $476 to $821
- Valuation Model Target Price: around $880
- Implied Upside: 41%
Analyze your favorite stocks like Regeneron Pharmaceuticals with TIKR (It’s free) >>>
What Happened?
Regeneron Pharmaceuticals, Inc. stock fell about 15% over the past 30 days, recently trading near $622 per share as investors questioned whether the company’s biggest growth drivers can offset another pipeline setback in 2026. The market’s focus has shifted from Regeneron’s strong Dupixent growth to a tougher debate: whether EYLEA HD can protect the company’s eye-disease franchise, whether the oncology pipeline can still create new value, and whether Regeneron can keep pace with major drugmaker peers such as Merck, Bristol Myers Squibb, Roche, Sanofi, and Bayer.
Regeneron recently reported revenue of $3.6 billion, up 19% year over year, and non-GAAP EPS of $9.47, but the stock still weakened as investors looked past the earnings beat and focused on future growth durability.
The stock moved lower because Regeneron’s fianlimab and Libtayo combination failed to significantly delay cancer progression versus Merck’s Keytruda in a Phase 3 melanoma study, damaging confidence in one of the company’s more important oncology programs. Fianlimab is a LAG-3 antibody designed to help the immune system attack tumors, while Libtayo is Regeneron’s existing PD-1 cancer drug, so the trial was important because it could have strengthened Regeneron’s position against Keytruda and Bristol Myers Squibb’s Opdualag in melanoma. The study still showed about a 5-month median progression-free survival benefit for the high-dose combination, but it missed statistical significance, which made the result less useful commercially and gave investors a clear reason to sell the stock.
Analyst actions made the decline worse. Citi downgraded Regeneron to Neutral and cut its price target to $700 from $900, while Reuters reported that at least 10 brokerages reduced price targets after the melanoma trial update. Those cuts matter because Wall Street is now assigning less value to Regeneron’s pipeline heading into the rest of 2026, especially as investors also watch competition in EYLEA, Regeneron’s eye-disease drug franchise, where the higher-dose EYLEA HD product is supposed to help offset pressure from biosimilars and Roche’s Vabysmo on the older 2-milligram version.
At the recent Bank of America Global Healthcare Conference, management tried to refocus investors on the parts of the business still working. Regeneron said Dupixent, its major inflammatory-disease drug co-developed with Sanofi, now has 1.4 million patients on therapy worldwide, nine U.S. indications, and an annual run rate of about $20 billion, with Executive Vice President Marion McCourt saying Dupixent is “first and best in category.” EYLEA HD also remains a key swing factor, as management said the higher-dose eye drug now represents almost half of the innovative branded EYLEA franchise’s net sales, with roughly 10% demand growth expected in the coming quarter while the older 2-milligram EYLEA product continues to decline in the mid- to high-teens range.
Value Regeneron Pharmaceuticals instantly (Free with TIKR) >>>
Is REGN Undervalued?
Under valuation assumptions, the stock is modeled using:
- Revenue Growth (CAGR): 10%
- Operating Margins: 37%
- Exit P/E Multiple: 13x
Regeneron’s valuation case depends on whether Dupixent can keep expanding across asthma, atopic dermatitis, COPD, and other inflammatory diseases while EYLEA HD defends the company’s eye-care business from biosimilar and branded competition.
Analyst estimates still point to revenue rising from about $14 billion in 2025 to about $21 billion by 2030, which suggests the market is not pricing Regeneron like a broken growth story.
See analysts’ growth forecasts and price targets for Regeneron Pharmaceuticals (It’s free) >>>
The 10% revenue growth assumption depends on Dupixent adding more patients across existing and newer indications, EYLEA HD taking enough share to soften declines in the older EYLEA product, and Regeneron finding new pipeline wins after the fianlimab setback.
The 37% margin assumption matters because Regeneron still spends heavily on R&D, so earnings power depends on keeping high-value products growing fast enough to absorb pipeline investment without major margin pressure.
Based on these inputs, the model estimates a target price of around $880, implying about 41% total upside, suggesting Regeneron appears undervalued if Dupixent growth, EYLEA HD execution, and pipeline rebuilding stay on track through 2026.
How Much Upside Does REGN Stock Have From Here?
Investors can estimate Regeneron Pharmaceuticals’ potential share price, or what any stock could be worth, in under a minute using TIKR’s New Valuation Model tool.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
Value Regeneron Pharmaceuticals in under 60 seconds with TIKR (It’s free) >>>
